Regeneron (REGN) Tops Q1 EPS by $1.45
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Regeneron Reports First Quarter 2022 Financial and Operating Results
May 4, 2022 6:30 AM EDTTARRYTOWN, N.Y., May 4, 2022 /PRNewswire/ --
First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 25%First quarter 2022 EYLEA® U.S. net sales increased 13% to $1.52 billion versus first quarter 2021First quarter 2022 Dupixent® global net sales(c)(recorded by Sanofi) increased 43% to $1.81 billion versus first quarter 2021First quarter 2022 GAAP diluted EPS of $8.61; non-GAAP diluted EPS(a) of $11.49Dupixent approved in EU for children aged 611 years with severe asthma; FDA priority review... More